Opportunity
Federal Register #337-TA-1466
ITC Terminates Investigation into Antibody Drug Conjugates and Components
Buyer
U.S. International Trade Commission
Posted
July 07, 2026
Identifier
337-TA-1466
This notice announces the termination of a U.S. International Trade Commission (ITC) investigation into certain antibody drug conjugates and their components. - Government Buyer: - U.S. International Trade Commission (ITC) - OEMs and Vendors Mentioned: - AbbVie Inc. - ImmunoGen, Inc. - ImmunoGen Switzerland GmbH - ProfoundBio US Co. - ProfoundBio (Suzhou) Co., Ltd. - Genmab A/S - Genmab B.V. - Genmab US, Inc. - Products/Services: - Antibody drug conjugates and components thereof - Products containing the same - Unique/Notable Requirements: - The investigation was based on alleged misappropriation of trade secrets under section 337 of the Tariff Act of 1930 - The investigation has been terminated in its entirety following the withdrawal of the complaint - No procurement or award is associated with this notice
Description
The U.S. International Trade Commission has determined not to review an initial determination terminating the investigation into certain antibody drug conjugates and components thereof, and products containing the same. The investigation was based on allegations of trade secret misappropriation and its impact on the U.S. industry. The investigation has been terminated in its entirety following the withdrawal of the complaint by the complainants.